LOADING

Type to search

COVID-19 preparedness: capability to fabricate vaccines, therapeutics and diagnostics in sub-Saharan Africa | Globalization and Well being

Social

COVID-19 preparedness: capability to fabricate vaccines, therapeutics and diagnostics in sub-Saharan Africa | Globalization and Well being

Share

  • 1.

    Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–4.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • 2.

    El-Sadr WM, Justman J. Africa in the path of Covid-19. N Engl J Med. 2020;383(3):e11.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 3.

    Gilbert M, Pullano G, Pinotti F, Valdano E, Poletto C, Boëlle PY, et al. Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. Lancet. 2020;395(10227):871–7.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 4.

    Paintsil E. COVID-19 threatens health systems in sub-Saharan Africa: the eye of the crocodile. J Clin Invest. 2020;130(6):2741–4.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • 5.

    Nachega J, Seydi M, Zumla A. The late arrival of coronavirus disease 2019 (COVID-19) in Africa: mitigating Pan-continental spread. Clin Infect Dis. 2020;71(15):875–8.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 6.

    Farrell TW, Francis L, Brown T, Ferrante LE, Widera E, Rhodes R, et al. Rationing limited healthcare resources in the COVID-19 era and beyond: ethical considerations regarding older adults. J Am Geriatr Soc. 2020;68(6):1143–9.

    PubMed 
    Article 

    Google Scholar 

  • 7.

    Jessop ZM, Dobbs TD, Ali SR, Combellack E, Clancy R, Ibrahim N, et al. Personal protective equipment (PPE) for surgeons during COVID-19 pandemic: a systematic review of availability, usage, and rationing. Br J Surg. 2020;107(10):1262–80.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 8.

    Rosenbaum L. Facing Covid-19 in Italy – ethics, logistics, and therapeutics on the Epidemic’s front line. N Engl J Med. 2020;382(20):1873–5.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • 9.

    White DB, Lo B. A framework for rationing ventilators and critical care beds during the COVID-19 pandemic. Jama. 2020;323(18):1773–4.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 10.

    Nachega JB, Grimwood A, Mahomed H, Fatti G, Preiser W, Kallay O, et al. From easing lockdowns to scaling-up community-based COVID-19 screening, testing, and contact tracing in Africa – shared approaches, innovations, and challenges to minimize morbidity and mortality. Clin Infect Dis. 2020;ciaa695.

  • 11.

    Africa Centers for Disease Control. Guidance for Assessment, Monitoring, and Movement Restrictions of People at Risk for COVID-19 in Africa 2020 [Available from: https://africacdc.org/download/africa-cdc-guidance-for-assessment-monitoring-and-movement-restrictions-of-people-at-risk-for-covid-19-in-africa/?ind=1584446376355&filename=Assessment-Monitoring-Movement-Restrictions-COVID-19-Africa.pdf&wpdmdl=3456&refresh=5fa35b68eead81604541288. Accessed: 29 Oct 2020.

  • 12.

    Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob Health. 2020;8(4):e488–e96.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 13.

    ClinicalTrials.gov. COVID-19 Vaccine Trials. 2020 [Available from: https://clinicaltrials.gov/ct2/results?recrs=ab&type=Intr&cond=Covid19&intr=%22Vaccines%22. Accessed: 5 Nov 2020].

  • 14.

    Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–78.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 15.

    Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427–38.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 16.

    Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–54.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 17.

    Bhattacharya R, Chowdhury S, Mukherjee R, Nandi A, Kulshrestha M, Ghosh R, et al. Pre exposure hydroxychloroquine prophylaxis for covid-19 in healthcare workers: a retrospective cohort. medRxiv. 2020; 2020.06.09.20116806.

  • 18.

    Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as Postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517–25.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 19.

    Cuadrado-Lavín A, Olmos JM, Cifrian JM, Gimenez T, Gandarillas MA, García-Saiz M, et al. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):472.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar 

  • 20.

    Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 – final report. N Engl J Med. 2020;383(19):1813–26.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • 21.

    Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of Remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327–36.

    CAS 
    Article 

    Google Scholar 

  • 22.

    Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–78.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 23.

    Pan H, Peto R, Karim QA, Alejandria M, Henao-Restrepo AM, García CH, et al. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv. 2021;384(6):497-511.

  • 24.

    Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19 – preliminary report. N Engl J Med. 2020;NEJMoa2021436.

  • 25.

    ClinicalTrials.gov NCT04379336. Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial 2020 [Available from: https://clinicaltrials.gov/ct2/show/NCT04379336?recrs=ab&cond=Covid19&cntry=ZA&draw=2&rank=4. Accessed: 5 Nov 2020.

    Google Scholar 

  • 26.

    GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun. 2020;11(1):3436.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar 

  • 27.

    Soliman R, Brassey J, Plüddemann A, Heneghan C. Does BCG vaccination protect against acute respiratory infections and COVID-19? A rapid review of current evidence 2020. [Available from: https://www.cebm.net/covid-19/does-bcg-vaccination-protect-against-acute-respiratory-infections-and-covid-19-a-rapid-review-of-current-evidence/. Accessed: 5 Nov 2020.

    Google Scholar 

  • 28.

    Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. Lancet. 2020;395(10236):1545–6.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 29.

    NCT04384549 Cg. Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers (COVID-BCG) 2020 [Available from: https://clinicaltrials.gov/ct2/show/NCT04384549. Accessed: 20 June 2020.

    Google Scholar 

  • 30.

    Gopalaswamy R, Ganesan N, Velmurugan K, Aravindhan V, Subbian S. The strange case of BCG and COVID-19: the verdict is still up in the air. Vaccines (Basel). 2020;8(4):612.

    PubMed Central 
    Article 

    Google Scholar 

  • 31.

    Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, et al. Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med. 2018;379(2):138–49.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 32.

    Biering-Sørensen S, Aaby P, Lund N, Monteiro I, Jensen KJ, Eriksen HB, et al. Early BCG-Denmark and neonatal mortality among infants weighing <2500 g: a randomized controlled trial. Clin Infect Dis. 2017;65(7):1183–90.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 33.

    de Chaisemartin C, de Chaisemartin L. BCG vaccination in infancy does not protect against COVID-19. Evidence from a natural experiment in Sweden. Clin Infect Dis. 2020:ciaa1223.

  • 34.

    ClinicalTrials.gov NCT04444674. COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults with and without HIV-infection 2020 [Available from: https://clinicaltrials.gov/ct2/show/NCT04444674?term=Vaccine&cond=Covid-19&cntry=ZA&draw=2&rank=2. Accessed: 5 Nov 2020 ].

  • 35.

    ClinicalTrials.gov NCT04553016. A Phase 1 Trial of ChAdOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern Africa. 2020 [Available from: https://clinicaltrials.gov/ct2/show/NCT04553016?term=ChAdOx1&map_cntry=KE&draw=2&rank=1]. Accessed: 5 Nov 2020.

  • 36.

    Makoni M. COVID-19 vaccine trials in Africa. Lancet Respir Med. 2020;8(11):e79–80.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 37.

    World Health Organization. Q&A on the Phase 3 trial results for malaria vaccine RTS,S/AS01 2017 [Available from: https://www.who.int/malaria/media/rtss-phase-3-trial-qa/en/. Accessed: 5 Nov 2020.

  • 38.

    Mugerwa RD, Kaleebu P, Mugyenyi P, Katongole-Mbidde E, Hom DL, Byaruhanga R, et al. First trial of the HIV-1 vaccine in Africa: Ugandan experience. Bmj. 2002;324(7331):226–9.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 39.

    Tameris M, McShane H, McClain JB, Landry B, Lockhart S, Luabeya AK, et al. Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. Tuberculosis (Edinb). 2013;93(2):143–9.

    CAS 
    Article 

    Google Scholar 

  • 40.

    Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389(10068):505–18.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 41.

    Laher F, Bekker LG, Garrett N, Lazarus EM, Gray GE. Review of preventative HIV vaccine clinical trials in South Africa. Arch Virol. 2020;165(11):2439–52.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 42.

    Lhomme E, Modet C, Augier A, Faye S, Dabakuyo-Yonli TS, Levy-Marchal C, et al. Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context. Trials. 2019;20(1):422.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar 

  • 43.

    Innovative Medicines Initiative. Trial of second Ebola vaccine to start in Democratic Republic of the Congo. 2019 October 31. [Available from: https://www.imi.europa.eu/news-events/newsroom/trial-second-ebola-vaccine-start-democratic-republic-congo. Accessed: 5 Nov 2020].

  • 44.

    Ampofo W. Vaccine manufacturing in Africa: Self-sufficiency-a need? Or a dream? No date. [Available from: https://www.who.int/immunization/research/forums_and_initiatives/1_Wlliam_Ampofo_Vaccine_Manufacturing_Africa.pdf?ua=1. Accessed: 5 Nov 2020].

  • 45.

    Nkengasong JN, Ndembi N, Tshangela A, Raji T. COVID-19 vaccines: how to ensure Africa has access. Nature. 2020;586(7828):197–9.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • 46.

    Choy KT, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KPY, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antivir Res. 2020;178:104786.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 47.

    Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 48.

    Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • 49.

    Brown AJ, Won JJ, Graham RL, Dinnon KH 3rd, Sims AC, Feng JY, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir Res. 2019;169:104541.

    CAS 
    Article 

    Google Scholar 

  • 50.

    Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y, et al. Efficacy and safety of Lopinavir/ritonavir or Arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Med (N Y). 2020;1(1):105-13.e4.

    Google Scholar 

  • 51.

    Doward J, Gbinigie K. Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19 2020 April 14. [Available from: https://www.cebm.net/covid-19/lopinavir-ritonavir-a-rapid-review-of-the-evidence-for-effectiveness-in-treating-covid/. Accessed: 5 Nov 2020].

  • 52.

    Baroutjian A, Sanchez C, Boneva D, McKenney M, Elkbuli A. SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence. Am J Emerg Med. 2020;38(11):2405–15.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 53.

    Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209:107512.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 54.

    Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020.

  • 55.

    US Food and Drug Administration. Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment. 2020 [Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment. Accessed: 26 June 2020].

    Google Scholar 

  • 56.

    The Times of India. India approves emergency use of remdesivir to treat COVID-19 2020 June 2. [Available from: https://timesofindia.indiatimes.com/india/india-approves-emergency-use-of-remdesivir-to-treat-covid-19-patients/articleshow/76152949.cms. Accessed: 5 Nov 2020].

  • 57.

    Reuters. Singapore approves remdesivir drug for emergency COVID-19 treatment 2020 June 10. [Available from: https://www.reuters.com/article/us-health-coronavirus-singapore-remdesiv/singapore-approves-remdesivir-drug-for-emergency-covid-19-treatment-idUSKBN23H17F. Accessed: 5 Nov 2020].

  • 58.

    The Asahi Shimbun. Japan approves remdesivir for COVID-19 despite uncertainties 2020 May 8. [Available from: http://www.asahi.com/ajw/articles/13358075. Accessed: 5 Nov 2020].

  • 59.

    Dyer O. Covid-19: Remdesivir has little or no impact on survival, WHO trial shows. Bmj. 2020;371:m4057.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 60.

    Bloomberg. Gilead Chooses Middle Ground in Pricing of Its Coronavirus Drug 2020 June 29. [Available from: https://www.bloomberg.com/news/articles/2020-06-29/gilead-says-remdesivir-will-cost-2-340-for-five-day-treatment. Accessed: 5 Nov 2020.

  • 61.

    ClinicalTrials.gov. COVID-19 Trials Evaluating Chloroquine as Pre- or Post-Exposure Prevention 2020 [Available from: https://clinicaltrials.gov/ct2/results?cond=Covid19&term=prophylaxis&type=&rslt=&recrs=b&recrs=a&age_v=&gndr=&intr=%22chloroquine%22&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=. Accessed: 7 Nov 2020].

  • 62.

    Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, et al. Chloroquine and hydroxychloroquine for the prevention or treatment of COVID-19 in Africa: caution for inappropriate off-label use in healthcare settings. Am J Trop Med Hyg. 2020;102(6):1184–8.

    PubMed 
    Article 

    Google Scholar 

  • 63.

    Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-Centre, randomized, controlled trial. medRxiv. N Engl J Med. 2020;383(21):2030–40.

  • 64.

    Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383(21):2041–52.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • 65.

    Ayele Mega T, Feyissa TM, Dessalegn Bosho D, Kumela Goro K, Zeleke NG. The outcome of hydroxychloroquine in patients treated for COVID-19: systematic review and meta-analysis. Can Respir J. 2020;2020:4312519.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 66.

    ClinicalTrials.gov. COVID-19 Trials Evaluating Hydroxychloroquine as Pre- or Post-Exposure Prevention 2020 [Available from: https://clinicaltrials.gov/ct2/results?term=prophylaxis&recrs=ab&cond=Covid19&intr=%22Hydroxychloroquine%22. Accessed: 7 Nov 2020].

  • 67.

    Zhang TY, Zhong B. Meeting the potential emergency global drug supply challenge of hydroxychloroquine for COVID-19. Med Drug Discov. 2020;5:100036.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 68.

    The Hindu. India lifts export ban on hydroxychloroquine 2020 June 11 [Available from: https://www.thehindu.com/news/national/india-lifts-export-ban-on-hydroxychloroquine/article31806635.ece. Accessed: 5 Nov 2020].

  • 69.

    Nachega JB, Ishoso DK, Otokoye JO, Hermans MP, Machekano RN, Sam-Agudu NA, et al. Clinical characteristics and outcomes of patients hospitalized for COVID-19 in Africa: early insights from the Democratic Republic of the Congo. Am J Trop Med Hyg. 2020;103(6):2419–28.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 70.

    Ashinyo M, Duti V, Dubik S, Amegah K, Kutsoati K, Oduro-Mensah E, et al. Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. Pan Afr Med J. 2020;37(Suppl 1):9.

    PubMed 
    PubMed Central 

    Google Scholar 

  • 71.

    The East African. Uganda’s Cipla takes bold step to make ‘unpopular’ malaria drug 2020 [Available from: https://www.theeastafrican.co.ke/business/Uganda-Cipla-to-make-malaria-drug/2560-5549874-v6f1hpz/index.html. Accessed: 5 Nov2 020 ].

    Google Scholar 

  • 72.

    Hill A, Wang J, Levi J, Heath K, Fortunak J. Minimum costs to manufacture new treatments for COVID-19. J Virus Erad. 2020;6(2):61–9.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 73.

    Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, Singh BR, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020;19(1):23.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 74.

    Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res. 2020;178:104787.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 75.

    Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin and COVID-19: a report in antiviral research, widespread interest, an FDA warning, two letters to the editor and the authors’ responses. Antivir Res. 2020;178:104805.

    CAS 
    PubMed 
    Article 

    Google Scholar 

  • 76.

    World Health Organization. African Programme for Onchocerciasis Control (APOC) 2020 [Available from: https://www.who.int/apoc/cdti/ivermectin/en/. Accessed: 5 Nov 2020].

  • 77.

    World Health Organization. Clinical management of COVID-19: interim guidance 2020 [Available from: https://www.who.int/publications/i/item/clinical-management-of-covid-19. Accessed: 5 Nov 2020].

    Google Scholar 

  • 78.

    Gbinigie K, Frie K. What is the evidence for using macrolide antibiotics to treat COVID-19? 2020 [Available from: https://www.cebm.net/covid-19/what-is-the-evidence-for-use-of-macrolide-antobiotics-for-treatmetnof-covid-19/. Accessed: 5 Nov 2020].

    Google Scholar 

  • 79.

    Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog. 2020;145:104228.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 80.

    Oliver ME, Hinks TSC. Azithromycin in viral infections. Rev Med Virol. 2020:e2163.

  • 81.

    Ramireddy A, Chugh H, Reinier K, Ebinger J, Park E, Thompson M, et al. Experience with hydroxychloroquine and azithromycin in the coronavirus disease 2019 pandemic: implications for QT interval monitoring. J Am Heart Assoc. 2020;9(12):e017144.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 82.

    Shah RR. Chloroquine and hydroxychloroquine for COVID-19: perspectives on their failure in repurposing. J Clin Pharm Ther. 2021;46(1):17–27.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 83.

    Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–43.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 84.

    Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 85.

    Sinha P, Matthay MA, Calfee CS. Is a “cytokine storm” relevant to COVID-19? JAMA Intern Med. 2020;180(9):1152–4.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 86.

    Khan NA. Anakinra for severe forms of COVID-19. Lancet Rheumatol. 2020;2(10):e586–e7.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 87.

    Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–e31.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 88.

    Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393–400.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 89.

    Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–5.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 90.

    Morrison AR, Johnson JM, Griebe KM, Jones MC, Stine JJ, Hencken LN, et al. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. J Autoimmun. 2020;114:102512.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 91.

    Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 92.

    Antwi-Amoabeng D, Kanji Z, Ford B, Beutler BD, Riddle MS, Siddiqui F. Clinical outcomes in COVID-19 patients treated with tocilizumab: an individual patient data systematic review. J Med Virol. 2020;92(11):2516–22.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 93.

    Rilinger J, Kern WV, Duerschmied D, Supady A, Bode C, Staudacher DL, et al. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):470.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 94.

    Cotter A, Wallace D, McCarthy C, Feeney E, O’Neill L, Stack J, et al. The COVIRL002 trial-tocilizumab for management of severe, non-critical COVID-19 infection: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):758.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 95.

    Maes B, Bosteels C, De Leeuw E, Declercq J, Van Damme K, Delporte A, et al. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):468.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 96.

    Canadian Agency for Drugs and Technologies in Health. Tocilizumab (Actemra): adult patients with moderately to severely active rheumatoid arthritis. Table 1: cost-comparison table for biologic disease-modifying drugs for rheumatoid arthritis. 2015 [Available from: https://www.ncbi.nlm.nih.gov/books/NBK349513/table/T43/. Accessed: 6 Nov 2020].

    Google Scholar 

  • 97.

    Roche Pharmaceuticals. Our Product List. 2020. [Available from: https://www.roche.com/products/products-list~division=pharmaceuticals~.htm. Accessed: 6 Nov 2020].

    Google Scholar 

  • 98.

    EUSA Pharma. Our Products. 2020. [Available from: https://eusapharma.com/our-focus/our-products. Accessed: 6 Nov 2020].

    Google Scholar 

  • 99.

    Regeneron. Medicines. 2020. [Available from: https://www.regeneron.com/medicines/. Accessed: 6 Nov 2020].

    Google Scholar 

  • 100.

    Sweden Orphan Biovitrum. SOBI products. 2020. [Available from: https://www.sobi.com/en/products. Accessed: 6 Nov 2020].

    Google Scholar 

  • 101.

    Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020. https://doi.org/10.1038/s41591-020-1088-9.

  • 102.

    Valk SJ, Piechotta V, Chai KL, Doree C, Monsef I, Wood EM, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev. 2020;5(5):Cd013600.

    PubMed 

    Google Scholar 

  • 103.

    Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, Lamikanra A, Kimber C, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020;7(7):CD013600.

  • 104.

    Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). Bmj. 2020;371:m3939.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 105.

    Schwartz SP, Thompson P, Smith M, Lercher DM, Rimland CA, Bartelt L, et al. Convalescent plasma therapy in four critically ill pediatric patients with coronavirus disease 2019: a case series. Crit Care Explor. 2020;2(10):e0237.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 106.

    Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama. 2020;323(16):1582–9.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 107.

    Bakhtawar N, Usman M, Khan MMU. Convalescent plasma therapy and its effects on COVID-19 patient outcomes: a systematic review of current literature. Cureus. 2020;12(8):e9535.

    PubMed 
    PubMed Central 

    Google Scholar 

  • 108.

    Chowdhury FR, Hoque A, Chowdhury FUH, Amin MR, Rahim A, Rahman MM, et al. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: a structured summary of a study protocol of a phase II randomized controlled trial. Trials. 2020;21(1):883.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 109.

    Janssen M, Schäkel U, Djuka Fokou C, Krisam J, Stermann J, Kriegsmann K, et al. A randomized open label phase-II clinical trial with or without infusion of plasma from subjects after convalescence of SARS-CoV-2 infection in high-risk patients with confirmed severe SARS-CoV-2 disease (RECOVER): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):828.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 110.

    Eckhardt CM, Cummings MJ, Rajagopalan KN, Borden S, Bitan ZC, Wolf A, et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):499.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 111.

    Kreil TR, Mc Vey JK, Lei LS, Camacho L, Wodal W, Kerschbaum A, et al. Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza. Transfusion. 2012;52(4):803–9.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 112.

    Nordling L. Unproven herbal remedy against COVID-19 could fuel drug-resistant malaria, scientists warn. Science Magazine. May 6 2020. Available at: https://www.sciencemag.org/news/2020/05/unproven-herbalremedy-against-covid-19-could-fuel-drug-resistant-malaria-scientists. Accessed 18 Feb 2021.

  • 113.

    Wikipedia. Covid-organics. 2020. [Available from: https://en.wikipedia.org/wiki/Covid-Organics. Accessed: 6 Nov 2020].

    Google Scholar 

  • 114.

    World Health Organization. WHO supports scientifically-proven traditional medicine 2020 [Available from: https://www.afro.who.int/news/who-supports-scientifically-proven-traditional-medicine?gclid=Cj0KCQjw-_j1BRDkARIsAJcfmTFgtLJOcQKMB6h5OoeZ4sU_q5l2Xy80tI-Vrf-_XFSQpMlcGpblUDIaAqu6EALw_wcB. Accessed: 6 Nov 2020].

    Google Scholar 

  • 115.

    Africa Centres for Disease Control and Prevention. Statement on herbal remedies and medicines for prevention and treatment of COVID-19. 2020. [Available from: https://africacdc.org/download/statement-on-herbal-remedies-and-medicines-for-prevention-and-treatment-of-covid-19/. Accessed: 6 Nov 2020].

    Google Scholar 

  • 116.

    World Health Organization. Expert panel endorses protocol for COVID-19 herbal medicine clinical trials. 2020 [Available from: https://www.afro.who.int/news/expert-panel-endorses-protocol-covid-19-herbal-medicine-clinical-trials. Accessed: 6 Nov 2020].

    Google Scholar 

  • 117.

    Gilmore K, Zhou Y, Ramirez S, Pham LV, Fahnøe U, Feng S, et al. In vitro efficacy of artemisinin-based treatments against SARS-CoV-2. bioRxiv. 2020; 2020.10.05.326637.

  • 118.

    Xinhuanet News. Nigeria unveils drugs for treatment of Ebola, malaria 2018 [Available from: http://www.xinhuanet.com/english/2018-01/20/c_136909297.htm. Accessed: 6 Nov 2020.

    Google Scholar 

  • 119.

    Obayendo T. Breaking: NIPRD develops NIPRIMUNE for COVID-19 treatment: PharmaNews Online; 27 May 2020. Available at: https://www.pharmanewsonline.com/breaking-niprd-develops-niprimune-for-covid-19-treatment/. Accessed 18 Feb 2021.

  • 120.

    The Center of Awareness Food Supplement. CoA Mixture 2020 [Available from: https://www.coadrugs.org/coamixture/. Accessed: 6 Nov 2020].

  • 121.

    AllAfrica.com. Ghana: COA FS, 8 Other Herbal Products Recommended As Immune Support, Treatment of COVID-19 2020 May 22 [Available from: https://allafrica.com/stories/202005220607.html. Accessed: 6 Nov 2020.

  • 122.

    Li H, Chen C, Hu F, Wang J, Zhao Q, Gale RP, et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia. 2020;34(6):1503–11.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 123.

    Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–5.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 124.

    Drugs.com. Dexamethasone prices, coupons, and patient assistance programs. 2020[Available from: https://www.drugs.com/price-guide/dexamethasone. Accessed: Accessed: 6 Nov 2020].

  • 125.

    PharmaOffer.com. Producers, Manufacturers and Traders of Dexamethasone 2020 [Available from: https://api.pharmaoffer.com/api-excipient-supplier/dexamethasone. Accessed: 6 Nov 2020].

  • 126.

    Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, et al. Association of Treatment Dose Anticoagulation with in-Hospital Survival among Hospitalized Patients with COVID-19. J Am Coll Cardiol. 2020;76(1):122–4.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 127.

    Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–9.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 128.

    Kamel AM, Sobhy M, Magdy N, Sabry N, Farid S. Anticoagulation outcomes in hospitalized Covid-19 patients: a systematic review and meta-analysis of case-control and cohort studies. Rev Med Virol. 2020:e2180.

  • 129.

    Lasky JA, Fuloria J, Morrison ME, Lanier R, Naderer O, Brundage T, et al. Design and rationale of a randomized, double-blind, placebo-controlled, phase 2/3 study evaluating Dociparstat in acute lung injury associated with severe COVID-19. Adv Ther. 2021;38(1):782–91.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 130.

    Marietta M, Vandelli P, Mighali P, Vicini R, Coluccio V, D’Amico R. Randomised controlled trial comparing efficacy and safety of high versus low low-molecular weight heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol. Trials. 2020;21(1):574.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 131.

    Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2020;8:Cd013705.

    PubMed 
    PubMed Central 

    Google Scholar 

  • 132.

    Oladipo EK, Ajayi AF, Odeyemi AN, Akindiya OE, Adebayo ET, Oguntomi AS, et al. Laboratory diagnosis of COVID-19 in Africa: availability, challenges and implications. Drug Discov Ther. 2020;14(4):153–60.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 133.

    Nkengasong J. Let Africa into the market for COVID-19 diagnostics. Nature. 2020;580(7805):565.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 134.

    Rubin R. The challenges of expanding rapid tests to curb COVID-19. JAMA Network. 2020;324(18):1813–5.

    CAS 

    Google Scholar 

  • 135.

    Vandenberg O, Martiny D, Rochas O, van Belkum A, Kozlakidis Z. Considerations for diagnostic COVID-19 tests. Nat Rev Microbiol. 2020:1–13.

  • 136.

    Africa Centres for Disease Control and Prevention. AU and Africa CDC launch Partnership to Accelerate COVID-19 Testing: Trace, Test and Track 2020 April 21 [Available from: https://africacdc.org/news-item/african-union-and-africa-centres-for-disease-control-and-prevention-launch-partnership-to-accelerate-covid-19-testing-trace-test-and-track/. Accessed: 6 Nov 2020].

  • 137.

    Musa HH, Musa TH, Musa IH, Musa IH, Ranciaro A, Campbell MC. Addressing Africa’s pandemic puzzle: perspectives on COVID-19 infection and mortality in sub-Saharan Africa. Int J Infect Dis. 2021;102:483–8.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 138.

    Bamgboye EL, Omiye JA, Afolaranmi OJ, Davids MR, Tannor EK, Wadee S, et al. COVID-19 pandemic: is Africa different? J Natl Med Assoc. 2020;S0027-9684(20)30345-X.

  • 139.

    Kirka D. AstraZeneca agrees to make COVID-19 vaccine for Europe. Medicaxpress. June 13 2020. Available at: https://apnews.com/article/67f340b026a2b385af86838618db6cff#:~:text=LONDON%20(AP)%20%E2%80%94%20Drugmaker%20AstraZeneca,race%20to%20combat%20the%20virus. Accessed 18 Feb 2021.

  • 140.

    Joseph S. AstraZeneca taps emergent as U.S. partner for potential COVID-19 vaccine. Reuters. June 11 2020. Available at: https://www.reuters.com/article/us-health-coronavirusastrazeneca-emerge/astrazeneca-taps-emergent-as-u-s-partner-for-potential-covid-19-vaccineidUKKBN23I23U. Accesed 18 Feb 2021.

  • 141.

    AstraZeneca. AstraZeneca takes next steps towards broad and equitable access to Oxford University’s COVID-19 vaccine. 2020 [Available from: https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-takes-next-steps-towards-broad-and-equitable-access-to-oxford-universitys-covid-19-vaccine.html. Accessed: 6 Nov 2020].

    Google Scholar 

  • 142.

    UNAIDS. The People’s Vaccine 2020 [Available from: https://www.unaids.org/en/resources/presscentre/featurestories/2020/may/20200514_covid19-vaccine-open-letter. Accessed: 7 Nov 2020].

  • 143.

    World Health Organization. International community rallies to support open research and science to fight COVID-19. 2020 [Available from: https://www.who.int/news/item/29-05-2020-international-community-rallies-to-support-open-research-and-science-to-fight-covid-19. Accessed: 6 Nov 2020].

    Google Scholar 

  • 144.

    World Health Organization. Global vaccine action plan 2011–2020 2013 [Available from: http://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/. Accessed: 6 Nov 2020].

    Google Scholar 

  • 145.

    Jadhav S, Gautam M, Gairola S. Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices. Clin Microbiol Infect. 2014;20(Suppl 5):37–44.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar 

  • 146.

    Africa Vaccine Manufacturing Initiative. Mission. 2019 [Available from: https://www.avmi-africa.org/about-us/mission/. Accessed: 7 Nov 2020].

    Google Scholar 

  • 147.

    Coalition for Epidemic Preparedness Innovations. Our Mission 2020 [Available from: https://cepi.net/about/whyweexist/. Accessed: 6 Nov 2020].

  • 148.

    Conway M, Holt T, Sabow A, Sun I. Should sub-Saharan Africa make its own drugs? : McKinsey and Company; 2019 [Available from: https://www.mckinsey.com/industries/public-and-social-sector/our-insights/should-sub-saharan-africa-make-its-own-drugs#. Accessed: 6 Nov 2020].

    Google Scholar 

  • 149.

    Kurian O. Expanding pharmaceutical local production in Africa: an idea whose time has come? Health express; 2019.

    Google Scholar 

  • 150.

    This Day. Bank Begins Disbursement of Loans to Boost Nigerian Health Sector 2020 May 29. [Available from: https://www.thisdaylive.com/index.php/2020/05/29/bank-begins-disbursement-of-loans-to-boost-nigerian-health-sector/. Accessed: 7 Nov 2020].

  • 151.

    World Health Organization. Measuring medicine prices, availability, affordability and price components 2008 [Available from: https://www.who.int/medicines/areas/access/medicines_prices08/en/. Accessed: 6 Nov 2020].

    Google Scholar 

  • 152.

    African Union Development Agency. African Medicines Regulatory Harmonisation 2019. [Available from: https://www.nepad.org/programme/african-medicines-regulatory-harmonisation-amrh. Accessed: 7 Nov 2020].

    Google Scholar 

  • 153.

    Sharma P. Indian Govt to set up dedicated parks for electronics and pharma companies 2020. [Available from: https://www.theweek.in/news/biz-tech/2020/03/21/govt-to-set-up-dedicated-parks-for-electronics-and-pharma-compan.html. Accessed: 7 Nov 2020].

    Google Scholar 

  • 154.

    Moshood Y. Anukwu Explains how Pharma Parks will Help Pharma Manufacturing Sector: PharmaNews Nigeria; 2019 [Available from: https://www.pharmanewsonline.com/anukwu-explains-how-pharma-parks-will-help-pharma-manufacturing-sector/. Accessed: 6 Nov 2020.

    Google Scholar 

  • 155.

    Jayakumar P. Coronavirus: Pharma to get Rs 10,000 crore boost; 3 ‘Bulk Drug Parks’ to be built 2020 [Available from: https://www.businesstoday.in/top-story/coronavirus-pharma-to-get-rs-10000-crore-boost-3-bulk-drug-parks-to-be-built/story/398901.html. Accessed: 7 Nov 2020].

    Google Scholar 

  • 156.

    African Development Bank Group. Ethiopia – Integrated Agro-Industrial Parks – Support Project (IAIPSP) – Appraisal Report 2019 [Available from: https://www.afdb.org/en/documents/ethiopia-integrated-agro-industrial-parks-support-project-iaipsp-appraisal-report. Accessed: 7 Nov 2020.

    Google Scholar 

  • 157.

    Ghosal A, Anna C. India, South Africa ask WTO to ease IP rules for COVID-19: Associated Press; 2020 [Available from: https://abcnews.go.com/Business/wireStory/india-south-africa-wto-ease-ip-rules-covid-73402812. Accessed: 7 Nov 2020.

  • 158.

    Coker M, Folayan MO, Michelow IC, Oladokun RE, Torbunde N, Sam-Agudu NA. Things must not fall apart: the ripple effects of the COVID-19 pandemic on children in sub-Saharan Africa. Pediatr Res. 2020. https://doi.org/10.1038/s41390-020-01174-y.

  • 159.

    Whitehead CL, Walker SP. Consider pregnancy in COVID-19 therapeutic drug and vaccine trials. Lancet. 2020;395(10237):e92.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 160.

    Bill and Melinda Gates Foundation. Bill & Melinda Gates Foundation, Wellcome, and Mastercard Launch Initiative to Speed Development and Access to Therapies for COVID-19 2020 March 10. [Available from: https://www.gatesfoundation.org/Media-Center/Press-Releases/2020/03/COVID-19-Therapeutics-Accelerator. Accessed: 7 Nov 2020].

  • 161.

    Africa Centres for Disease Control and Prevention. Africa CDC, FIND partner to build capacity for COVID-19 rapid diagnostic tests in Africa. 2020 [Available from: https://africacdc.org/news-item/africa-cdc-find-partner-to-build-capacity-for-covid-19-rapid-diagnostic-tests-in-africa. Accessed: 7 Nov 2020].

    Google Scholar 

  • Tags:

    You Might also Like

    Leave a Comment

    Your email address will not be published. Required fields are marked *